• Explore /
  • Poster
  • / Intensive first-line triplet chemotherapy plus cetuximab FIr-C/FOx-C in <em>RAS</em> wild-type MCRC: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.

Intensive first-line triplet chemotherapy plus cetuximab FIr-C/FOx-C in RAS wild-type MCRC: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.

Abstract Poster

Authors

null

Gemma Bruera

S. Salvatore Hospital, University of L'Aquila, L'Aquila, Italy

Gemma Bruera , Silvia Massacese , Antonella Dal Mas , Corrado Ficorella , Eugenio Ciacco , Giuseppe Calvisi , Maurizio Simmaco , Enrico Ricevuto

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Translational Research

Clinical Trial Registration Number

EudraCT 2009-016793-32

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr 673)

DOI

10.1200/JCO.2018.36.4_suppl.673

Abstract #

673

Poster Bd #

F10

Abstract Disclosures

Similar Posters

First Author: Takanori Watanabe

First Author: Akihito Tsuji

First Author: Sebastian Stintzing

First Author: Angela Damato